Peter Fernandes - 07 Jun 2023 Form 4 Insider Report for Bellerophon Therapeutics, Inc. (BLPH)

Role: Chief Executive Officer, Principal Financial and Accounting Officer
Signature: /s/ Peter Fernandes
Issuer symbol: BLPH
Transactions as of: 07 Jun 2023
Transactions value $: $0
Form type: 4
Filing time: 09 Jun 2023, 16:12:06 UTC
Previous filing: 14 Feb 2023
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BLPH	Stock Options (Right to Buy)	Award	$0	-100,000	-50%	$0	100,000	07 Jun 2023	Common Stock	100,000	$0.8264	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was approved by the Compensation Committee of the Board of Directors of Bellerophon Therapeutics, Inc., on February 10, 2023, contingent upon stockholder approval of an amendment to the Company's 2015 Equity Incentive Plan under which the options were granted, which was approved by stockholders on June 7, 2023.
F2	This option vests in 16 quarterly installments commencing on the date hereof.

Remarks:

Chief Executive Officer, Principal Financial and Accounting Officer